To evaluate the dosimetric performance of MAXPOINT-generated array layouts for patients with brainstem gliomas in comparison to standard array layouts.
Approach:
Patient Selection: Seven patients with brainstem gliomas were included based on specific eligibility criteria, including radiographic diagnosis and availability of suitable imaging.
TTFields Planning Software: The MAXPOINT® TTFields planning system was utilized for simulations, allowing for individualized treatment planning.
Target Segmentation: MRI and CT imaging were used for segmentation, defining gross tumor volume (GTV), peritumoral brain zone (PBZ), and clinical target volume (CTV).
Array Layout Generation: Automated finite element modeling generated voxel-level tissue models, and treatment plans were optimized to maximize local minimum power density (LMiPD) while maintaining realistic scalp positioning.
Key Findings:
MAXPOINT® allows for patient-specific modeling and planning for infratentorial tumors, including brainstem gliomas.
The study aimed to determine if local minimum field intensity (LMiFI) exceeded a reference value of 1 V/cm for therapeutic activity, which is significant for treatment efficacy.
Interpretation:
The study provides a framework for assessing the feasibility of TTFields in treating brainstem gliomas using advanced planning software, though further validation is needed.
Limitations:
The study was a simulation and no patients received actual TTFields treatment, which limits the applicability of the findings.
The sample size was limited to seven patients, which may affect the robustness of the conclusions.
Conclusion:
Further clinical validation is necessary to explore the role of TTFields in brainstem gliomas.
